Data Suggest AstraZeneca's Checkpoint Combo Could Hold Broader Promise In Lung Cancer
This article was originally published in Scrip
Executive Summary
AstraZeneca has published data in the Lancet Oncology which show that combination treatment with durvalumab (a PD-L1 inhibitor) and tremelimumab (a CTLA-4 inhibitor) has antitumor activity in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of their PD-L1 status.